FDA approval of Lyfgenia (lovotibeglogene autotemcel) for treatment of patients ages 12 and older with sickle cell disease and a history of vaso-occlusive events – bluebird bio
bluebird bio, Inc. announced the FDA has approved Lyfgenia (pronounced as ‘lif-JEN-ee-uh’) (lovotibeglogene autotemcel), also known as lovo-cel, for the treatment of sickle cell disease in patients ages… read more.
